LuminUltra Acquires Legionella Testing Business from Genomadix and Inks Strategic License to Commercialize Additional Tests for Ultra-portable Molecular Diagnostic Platform
LuminUltra (luminultra.com), the global leader in applied molecular diagnostics, today announced the acquisition of the legionella testing business assets of Genomadix Inc (genomadix.com), along with rights to develop and commercialize further assays and test methods in water, energy and food and beverage markets globally using the Genomadix Cube™ qPCR (quantitative polymerase chain reaction) Platform.
With this transaction, LuminUltra further expands its industry-leading portfolio of molecular testing solutions for rapid identification and quantification of the microbes within residential, commercial and industrial water systems that are responsible for causing the potentially deadly Legionnaire’s disease.
When paired with its easy-to-use automated test kit, the Genomadix Cube thermocycling platform will generate results that measure the presence and quantity of Legionella contamination in under one hour with laboratory-grade sensitivity. The elegant simplicity of the system allows any user in the field to quickly and accurately assess the level of contamination within their water system and take the actions necessary to minimize risk of outbreaks and operational downtime.
The industry leading legionella detection toolkit
“With this latest addition to our portfolio, we can now help even more customers around the world to rapidly and accurately monitor and manage against the proliferation of harmful Legionella bacteria,” said Pat Whalen, LuminUltra CEO. “This rapid, point of use solution complements our existing GeneCount® laboratory qPCR workflow and mail-in sample testing offerings by providing a best-in-class solution for those time sensitive, ‘in-field’ use cases that demand near-real-time and accurate results to confidently inform critical operational decisions and actions.”
Steve Edgett, CEO of Genomadix, added, “LuminUltra was the perfect home for the Legionella business that we nurtured under the Spartan Bioscience brand. We intend to support a seamless transition with our customers. We are thrilled that LuminUltra will bring scale, expertise, and focus to the Legionella business. Genomadix is focused on the development and commercialization of precision medicine tests on the Cube and licensing our CubeX Open Platform to strategic partners. This agreement is a win-win as LuminUltra will lead the development of new tests and expanded access to fast and accurate qPCR testing on CubeX for time-sensitive point of use applications in applied markets.”
The transaction was completed on July 31, 2024.
About LuminUltra
Founded in 1995, LuminUltra is a biological diagnostic testing company headquartered in Canada with operations in six countries. Widely recognized as the global leader in applied molecular diagnostics for the water, energy and food & beverage markets, it was also a key supplier of COVID-19 clinical testing reagents to the Government of Canada. Customers in over 80 countries trust LuminUltra’s technology, production reliability and history of customer service excellence to deliver their essential services in a safe-state. At the same time, LuminUltra fosters a culture of innovation and agility and is on an accelerated growth path, acquiring multiple companies in recent years and forming a partnership with the specialized private equity firm XPV Water Partners.
About Genomadix
Based in Ottawa, Canada, Genomadix Inc. is a pioneer in real-time qPCR point of need technology. The Genomadix Cube is a molecular diagnostic instrument capable of performing tests for precision medicine genotyping on a sample-to-result platform. The portable size, ease of use, and on-demand processing capability enables users to generate time-critical results in approximately one hour. The Cube platform is also available as an open platform called CubeX that can be used to design, develop and run any qPCR test for research and product development use. Applications of the Genomadix Cube technology include but are not limited to precision medicine, clinical and environmental. For more information, visit www.genomadix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909727336/en/
Contacts
Media: Gene Schilling, Director of Marketing
gene.schilling@luminultra.com +1-519-990-0084
Media: Chelsey Martellacci, Marketing Manager
media@genomadix.com 1-888-810-7788
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Launches AI Security Fabric, Providing AI Runtime Security for Agentic AI and LLM-Powered Applications11.12.2025 10:00:00 EET | Press release
AI is one of the fastest-growing technologies in the history of modern business, with the ability to revolutionize industries, optimize operations, and drive innovation, but it is also introducing security gaps, risks, and vulnerabilities. According to McKinsey, 78% of organizations are using AI in at least one business function, up from 55% two years ago. As a result, 73% of them are investing in AI-specific security tools, either with new or existing budgets, according to the 2025 Thales Data Threat Report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211710650/en/ Thales AI Security Fabric Thales is introducing the first foundational capabilities of its AI Security Fabric to protect the core and edge of enterprises' AI ecosystems. Thales AI Security Fabric – Safeguarding LLM-Powered Apps, Data, and Identities With Thales AI Security Fabric, organizations will be able to: Unlock AI-driven growth securely: Maximize AI’
Interactive Brokers Adds Access to Brazil’s B3 Exchange11.12.2025 10:00:00 EET | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced that eligible clients outside of Brazil can now trade Brazilian equities through B3, the Brazil Stock Exchange. This expansion gives investors more ways to access emerging market opportunities across Latin America alongside global stocks, options, futures, currencies, bonds, funds, and more through a single unified platform. The B3 Exchange is one of the most active and liquid markets in the region. With this addition, investors will have direct access to trade Brazilian equities, plus over 160 markets worldwide using Interactive Brokers’ powerful trading platforms and tools. “Global investors need seamless access to diverse markets to stay competitive,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “By adding Brazil’s B3 Exchange, we’re giving our clients efficient, low-cost access to one of the world’s most dynamic emerging economies through our unified global platform.” Int
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman11.12.2025 09:30:00 EET | Press release
Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors’ decision to appoint Abdul Mullick, Ph.D., currently President and Chief Operating Officer (COO), to the role of President and Chief Executive Officer (CEO). The appointment will become effective March 2026 following the conclusion of the Ordinary General Meeting of Shareholders. As Mullick takes on the role of President and CEO for Kyowa Kirin, current CEO Masashi Miyamoto, Ph.D., remains Chairman. In March 2025, shareholders approved a dual CEO / COO model, with Mullick appointed to the newly created role of Chief Operating Officer, partnering with Miyamoto to lead the global organisation. The model provided a transition period for Mullick to gain greater insights and understanding of the Japanese company, as the first non-Japanese CEO in the company’s long history. By reverting to the single leader model under Mullick in 2026, Kyowa Kirin aims
Tosi solmi merkittävän sopimuksen johtavan midstream-yhtiön EPIC Cruden kanssa11.12.2025 09:07:00 EET | Tiedote
OT-kyberturvallisuusalustojen globaali johtaja Tosi vahvistaa toimintaansa Yhdysvalloissa, ja yhtiö on solminut merkittävän tilaussopimuksen raakaöljyn kuljetuspalveluja tarjoavan johtavan midstream-toimijan EPIC Cruden kanssa. Aiemmin tänä vuonna solmittu arvoltaan kuusinumeroinen tilaussopimus on Tosin historian suurin. Sopimus vahvistaa merkittävästi Tosin asemaa öljy- ja kaasuteollisuudessa. Sopimus kattaa OT-verkkoinfrastruktuurin kokonaisvaltaisen korvaamisen uudella ratkaisulla sekä jatkuvan ylläpidon EPIC Cruden laaja-alaisissa toiminnoissa. EPIC Crudella on eri puolilla Texasia putkistoa 800 mailin pituudelta yhdistäen Delawaren, Midlandin ja Eagle Fordin öljykentät Meksikonlahden markkinoihin. EPIC Crude valitsi liiketoimintansa muuttuessa Tosin toimittamaan nopean, skaalautuvan ja kustannustehokkaan ratkaisun yhtiön nykyisen kuitupohjaisen verkon tilalle. Ennen käyttöönottoa Tosin tiimi perehtyi konsultoivalla lähestymistavalla EPIC Cruden liiketoimintavaatimuksiin. Tältä po
Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin11.12.2025 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic Pruritus of Unknown Origin (CPUO). The first patient of the trial – which is taking place in the United States – was enrolled at Dr. Vlada Groysman’s site in Birmingham, Alabama. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210261871/en/ CPUO is an underdiagnosed condition defined as itch lasting for more than six weeks without an identified cause.1 It is a common condition and prevalent in nearly 30% of the elderly in certain populations, but despite its debilitating impact – with effects on sleep, mental health, and overall quality of life – there are currently no approved treatments.1,7 Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom